SUPERNUS PHARMACEUTICALS, INC. Gain (Loss) on Derivative Instruments, Net, Pretax
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $76.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-01.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2019-03-01
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2017-06-30 was $23.00K, a 81.30% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2017-03-31 was $54.00K, a 46.53% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2017 was $76.00K, a 83.04% decline from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2016 was $448.00K, a 132.12% increase from fiscal 2015.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2015 was $193.00K, a 93.13% decline from fiscal 2014.
- SUPERNUS PHARMACEUTICALS, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2014 was $2.81M.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $23.00K derived: sum of 3 quarters · filed 2019-03-01 | $76.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $23.00K derived: sum of 2 quarters · filed 2018-11-09 | $76.00K 10-Q · filed 2018-11-09 | $176.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $23.00K 10-Q · filed 2018-08-09 | $76.00K 10-Q · filed 2018-08-09 | $176.00K derived: sum of 3 quarters · filed 2019-03-01 | $301.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $54.00K 10-Q · filed 2018-05-10 | $153.00K derived: sum of 2 quarters · filed 2019-03-01 | $278.00K derived: sum of 3 quarters · filed 2019-03-01 | $401.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $224.00K derived: sum of 2 quarters · filed 2019-03-01 | $347.00K derived: sum of 3 quarters · filed 2019-03-01 | $448.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | $125.00K 10-Q · filed 2017-11-09 | $248.00K derived: sum of 2 quarters · filed 2017-11-09 | $349.00K 10-Q · filed 2017-11-09 | $476.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $123.00K 10-Q · filed 2017-08-03 | $224.00K 10-Q · filed 2017-08-03 | $351.00K derived: sum of 3 quarters · filed 2018-03-01 | $465.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $101.00K 10-Q · filed 2017-05-09 | $228.00K derived: sum of 2 quarters · filed 2018-03-01 | $342.00K derived: sum of 3 quarters · filed 2018-03-01 | $343.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $127.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $241.00K derived: sum of 2 quarters · filed 2018-03-01 | $242.00K derived: sum of 3 quarters · filed 2018-03-01 | $193.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | $114.00K 10-Q/A · filed 2017-01-20 | $115.00K derived: sum of 2 quarters · filed 2017-01-23 | $66.00K 10-Q/A · filed 2017-01-20 | $760.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $1.00K 10-Q/A · filed 2017-01-23 | -$48.00K 10-Q/A · filed 2017-01-23 | $646.00K derived: sum of 3 quarters · filed 2017-03-16 | $1.41M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$49.00K 10-Q/A · filed 2017-01-20 | $645.00K derived: sum of 2 quarters · filed 2017-03-16 | $1.41M derived: sum of 3 quarters · filed 2017-03-16 | $2.08M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $694.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $1.45M derived: sum of 2 quarters · filed 2017-03-16 | $2.13M derived: sum of 3 quarters · filed 2017-03-16 | $2.81M 10-K · filed 2017-03-16 |
| 2014-09-30 | $760.00K 10-Q/A · filed 2017-01-20 | $1.44M derived: sum of 2 quarters · filed 2017-01-20 | $2.12M 10-Q/A · filed 2017-01-20 | $1.45M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-06-30 | $678.00K 10-Q · filed 2015-08-07 | $1.35M 10-Q · filed 2015-08-07 | $693.00K derived: sum of 3 quarters · filed 2017-01-20 | -$3.46M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-03-31 | $677.00K 10-Q · filed 2015-05-06 | $15.00K derived: sum of 2 quarters · filed 2017-01-20 | -$4.14M derived: sum of 3 quarters · filed 2017-01-20 | -$12.76M derived: sum of 4 quarters · filed 2017-01-20 |
| 2013-12-31 | -$662.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | -$4.82M derived: sum of 2 quarters · filed 2017-01-20 | -$13.43M derived: sum of 3 quarters · filed 2017-01-20 | -$13.35M 10-K/A · filed 2017-01-20 |
| 2013-09-30 | -$4.15M 10-Q · filed 2014-11-12 | -$12.77M derived: sum of 2 quarters · filed 2014-11-12 | -$12.69M 10-Q · filed 2014-11-12 | -$12.64M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | -$8.62M 10-Q · filed 2014-08-12 | -$8.54M 10-Q · filed 2014-08-12 | -$8.48M derived: sum of 3 quarters · filed 2015-03-12 | -$8.78M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $80.00K 10-Q · filed 2014-05-13 | $136.00K derived: sum of 2 quarters · filed 2015-03-12 | -$158.00K derived: sum of 3 quarters · filed 2015-03-12 | -$302.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$238.00K derived: sum of 2 quarters · filed 2015-03-12 | -$382.00K derived: sum of 3 quarters · filed 2015-03-12 | -$710.00K 10-K · filed 2015-03-12 |
| 2012-09-30 | -$294.00K 10-Q · filed 2013-11-13 | -$438.00K derived: sum of 2 quarters · filed 2013-11-13 | -$766.00K 10-Q · filed 2013-11-13 | |
| 2012-06-30 | -$144.00K 10-Q · filed 2013-08-14 | -$472.00K 10-Q · filed 2013-08-14 | ||
| 2011-12-31 | -$85.00K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |